| 15.25 0.22 (1.46%) | 05-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.88 | 1-year : | 30.18 |
| Resists | First : | 21.3 | Second : | 25.84 |
| Pivot price | 17.85  |
|||
| Supports | First : | 13.96 | Second : | 11.61 |
| MAs | MA(5) : | 15.4 |
MA(20) : | 19.35 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -2.6  |
Signal : | -2.4 |
| %K %D | K(14,3) : | 16.1 |
D(3) : | 15.4 |
| RSI | RSI(14): 30.3 |
|||
| 52-week | High : | 30.6 | Low : | 13.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KYTX ] has closed above bottom band by 24.8%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 16.45 - 16.53 | 16.53 - 16.6 |
| Low: | 14.62 - 14.71 | 14.71 - 14.79 |
| Close: | 15.11 - 15.24 | 15.24 - 15.37 |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Mon, 12 Feb 2024
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to ... - Yahoo Finance
Thu, 08 Feb 2024
Kyverna Therapeutics prices initial $319M offering at $22 per share (Pending:KYTX) - Seeking Alpha
Wed, 07 Feb 2024
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering - PR Newswire
Fri, 02 Feb 2024
Kyverna Looks to Go Public, Raise $182M Amid Surge in Biotech IPOs - BioSpace
Thu, 01 Feb 2024
Kyverna Therapeutics Aims For $200 Million IPO To Treat Autoimmune Diseases (NASDAQ:KYTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 41.4 (%) |
| Shares Short | 1,450 (K) |
| Shares Short P.Month | 626 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -54.9 % |
| Return on Equity (ttm) | -126 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|